Trial Condition(s):
Rosacea
Preferences & Treatment Satisfaction Drivers in Rosacea Patients
Bayer Identifier:
18575
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study Completed
Trial Purpose
To survey patients with rosacea about their rosacea treatment preferences as well as to assess potential drivers of rosacea treatment satisfaction.
Inclusion Criteria
- Male or female patients of at least 18 years of age at index date - At least one prescription for a topical rosacea treatments: Azelaic Acid Gel, Azelaic Acid Cream, Metronidazole Gel, Metronidazole Cream, Metronidazole Emulsion, Metronidazole Lotion, Brimonidine Tartrate Gel - At least one medical record with a diagnosis code for rosacea (ICD-9: 695.3) - At least 6 months of data history prior to the index date - Had at least one encounter at the Reliant Medical Group within 3 months prior to 01 January 2015
Exclusion Criteria
- None
Trial Summary
Enrollment Goal
206
Trial Dates
Phase
N/A
Could I receive a placebo?
No
Products
Finacea (Azelaic Acid, BAY39-6251)
Accepts Healthy Volunteers
No
Where to Participate
Loading...
Locations
| Locations | |
|---|---|
Locations Investigative Site Boston, United States | Contact Us: E-mail: [email protected] Phone: +49 30 300139003 |
Trial Design
A Study of Patient Preferences and Drivers of Treatment Satisfaction in Patients with Rosacea
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Self-reported concerns and importance of such concerns regarding their current topical rosacea treatmentsAssessed from the Rosacea Treatment Preference Questionnaire: Rated on a scale of 0 to 10, with 0 meaning not at all important and 10 meaning extremely importantTimeframe: Rosacea treatment in the past 4 weeks
Secondary Outcome
- Self-reported likelihood of switching to a topical rosacea treatmentsAssessed from the Rosacea Treatment Preference Questionnaire: Rated on a scale of 0 to 10, with 0 meaning not at all likely and 10 meaning extremely likelyTimeframe: Rosacea treatment in the past 4 weeks
- Quality of lifeMeasured using Dermatology Life Quality Index (DLQI): The DLQI consists of 10 questions concerning symptoms and feelings, daily activities, leisure, work, and school, personal relationships and treatmentTimeframe: Rosacea treatment in the past 4 weeks
- Treatment satisfactionAssessed by a score on the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q). Scores will be standardized and expressed as a 0-100 standardized scoreTimeframe: Rosacea treatment in the past 4 weeks
- Self-reported concerns and importance (a rating scale) of such concerns that patients would consider when switching to a new topical rosacea treatmentExtracted from the Rosacea Treatment Preference QuestionnaireTimeframe: Rosacea treatment in the past 4 weeks
Additional Information
Copyright © Bayer
Powered by
